SCHEMBL3497519

SCHEMBL3497519

COC(=O)C[C@H]1C[C@H](c2ccc(C#N)cc2)NC1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.37
HTT P42858 1/20 0.37
GAA P10253 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
KDM1A O60341 2/20 0.35
POLB P06746 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ALDH1A1 P00352 4/20 0.35
MAPT P10636 1/20 0.35
PGR P06401 1/20 0.34
KDM4E B2RXH2 3/20 0.34
KMT2A Q03164 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MITF O75030 1/20 0.34
ALOX12 P18054 1/20 0.34
RAB9A P51151 1/20 0.34
MDM2 Q00987 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3496537 1.00 KCNH2 (0.37) KCNH2HTTGAAL3MBTL1KDM1A
SCHEMBL3496540 1.00 KCNH2 (0.37) KCNH2HTTGAAL3MBTL1KDM1A
SCHEMBL3496534 1.00 KCNH2 (0.37) KCNH2HTTGAAL3MBTL1KDM1A
SCHEMBL3497520 1.00 KCNH2 (0.37) KCNH2HTTGAAL3MBTL1KDM1A
SCHEMBL3497464 0.80 MEN1 (0.37) GAAPOLBHSD17B10MAPTKMT2A
SCHEMBL3497466 0.80 MEN1 (0.37) GAAPOLBHSD17B10MAPTKMT2A
SCHEMBL3497631 0.80 MEN1 (0.37) GAAPOLBHSD17B10MAPTKMT2A
SCHEMBL3497634 0.80 MEN1 (0.37) GAAPOLBHSD17B10MAPTKMT2A
SCHEMBL3497471 0.80 MEN1 (0.37) GAAPOLBHSD17B10MAPTKMT2A
SCHEMBL3497635 0.80 MEN1 (0.37) GAAPOLBHSD17B10MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7659294-B2 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists MERCK & CO., INC. (US) 2010-02-09 US disclosed
US-20090042954-A1 2-(Aryl)Azacyclylmethyl Carboxylates, Sulfonates, Phosphonates, Phosphinates and Heterocycles as S1p Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-02-12 US disclosed
EP-1804793-A2 2-(ARYL)AZACYCLYLMETHYL CARBOXYLATES, SULFONATES, PHOSPHONATES, PHOSPHINATES AND HETEROCYCLES AS S1P RECEPTOR AGONISTS Merck & Co., Inc. (US) 2007-07-11 EP disclosed
WO-2006047195-A2 2-(ARYL)AZACYCLYLMETHYL CARBOXYLATES, SULFONATES, PHOSPHONATES, PHOSPHINATES AND HETEROCYCLES AS S1P RECEPTOR AGONISTS MERCK & CO., INC. (US) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042954-A1 2-(Aryl)Azacyclylmethyl Carboxylates, Sulfonates, Phosphonates, Phosphinates and Heterocycles as S1p Receptor Antagonists S1PR1, S1PR3, S1PR5 KCNH2 3277/4885HTT 4760/4885GAA 4468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.